Expression of Transmembrane Glycoprotein TROP2 in Triple-Negative Breast Cancer and It's Potential as a Molecular Classifier for Targeted Therapy.
1/5 보강
Trophoblast Cell-surface antigen 2 (TROP2), a calcium signal transducer & a transmembrane glycoprotein expression was studied in Triple-Negative Breast Cancer (TNBC) patients.
APA
Saravanan R, Balasubramanian V, et al. (2026). Expression of Transmembrane Glycoprotein TROP2 in Triple-Negative Breast Cancer and It's Potential as a Molecular Classifier for Targeted Therapy.. Cancer investigation, 44(1), 87-102. https://doi.org/10.1080/07357907.2025.2595303
MLA
Saravanan R, et al.. "Expression of Transmembrane Glycoprotein TROP2 in Triple-Negative Breast Cancer and It's Potential as a Molecular Classifier for Targeted Therapy.." Cancer investigation, vol. 44, no. 1, 2026, pp. 87-102.
PMID
41403267
Abstract
Trophoblast Cell-surface antigen 2 (TROP2), a calcium signal transducer & a transmembrane glycoprotein expression was studied in Triple-Negative Breast Cancer (TNBC) patients. mRNA expression, immunohistochemical and immunofluorescence analysis illustrated a higher TROP2 expression in the TNBC tissues. Assessment of tumor-infiltrating lymphocytes in TNBC samples was done and studies depicted a significant association between TROP2 expression and infiltration of CD4+ cells. Kaplan-Meier survival analysis observed TROP2 expression to be an independent determinant of survival, with better survival benefit in the TROP2 high group. Our study paves the way for newer therapies targeting TROP2 for TNBC patients.
🏷️ 키워드 / MeSH
- Humans
- Triple Negative Breast Neoplasms
- Female
- Antigens
- Neoplasm
- Cell Adhesion Molecules
- Middle Aged
- Biomarkers
- Tumor
- Adult
- Lymphocytes
- Tumor-Infiltrating
- Prognosis
- Molecular Targeted Therapy
- Aged
- Kaplan-Meier Estimate
- Gene Expression Regulation
- Neoplastic
- Indian cohort
- Overall survival
- TNBC
- TROP2
- Tumor infiltrating lymphocytes (TILs)